Management of interstitial lung disease in elderly patients

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 5, 2012, Pages 483-492

  Meyer, Keith C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

age; elderly patient; idiopathic pulmonary fibrosis; interstitial lung disease

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; ETANERCEPT; GAMMA1B INTERFERON; MACITENTAN; NINTEDANIB; PIRFENIDONE; PREDNISONE; SILDENAFIL; WARFARIN;

AGING; BRONCHOSCOPY; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; DNA METHYLATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; ELDERLY CARE; ENVIRONMENTAL EXPOSURE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LIVING WILL; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; OXIDATIVE STRESS; PATIENT EDUCATION; PROGNOSIS; RESUSCITATION; REVIEW; RHEUMATOID ARTHRITIS; TELOMERE SHORTENING; THORAX RADIOGRAPHY;

DISEASE MANAGEMENT; DISEASE SUSCEPTIBILITY; HEALTH SERVICES FOR THE AGED; HUMANS; LUNG DISEASES, INTERSTITIAL; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864867277     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283541337     Document Type: Review

References (74)

1. Meyer KC. Aging. Proc Am Thoracic Soc 2005; 2:433-439. (Pubitemid 43128039)
2. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A BiolSci Med Sci 2001; 56:M146-M156. (Pubitemid 32187141)
3. Meyer KC. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin Respir Crit Care Med 2010; 31:561-574.
4. Malafarina V, Uriz-Otano F, Iniesta R, et al. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas 2012; 71:109-114.
5. Selman M, Rojas M, Mora AL, et al. Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis. Semin Respir Crit Care Med 2010; 31:607-617.
6. Candore G, Caruso C, Jirillo E, et al. Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for antiageing strategies and successful ageing achievement. Curr Pharm Des 2010; 16:584-596.
7. Franceschi C, Monti D, Sansoni P, et al. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995; 16:12-16.
8. Wikby A, Johansson B, Ferguson F, et al. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol 1994; 29:531-541. (Pubitemid 24294545)
9. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010; 5:e8959.
10. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:810-816. (Pubitemid 44511663)
11. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949-1961.
12. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc 2011; 8:158-162.
13. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512.
14. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev 2008; 88:557-579. (Pubitemid 351522746)
15. Liu T, Hu B, Chung MJ, et al. Telomerase regulation of myofibroblast differentiation. Am J Respir Cell Mol Biol 2006; 34:625-633.
16. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008; 105:13051-13056.
17. Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172:417-422. (Pubitemid 41117386)
18. Jiang H, Schiffer E, Song Z, et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 2008; 105:11299-11304.
19. Christensen BC, Marsit CJ, Houseman EA, et al. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res 2009; 69:6315-6321.
20. Lanceta J, Prough RA, Liang R, et al. MicroRNA group disorganization in aging. Exp Gerontol 2010; 45:269-278.
21. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182:220-229.
22. Mora AL, RojasM. Aging and lung injury repair: a role for bone marrow derived mesenchymal stem cells. J Cell Biochem 2008; 105:641-647.
23. Ruzankina Y, Asare A, Brown EJ. Replicative stress, stem cells and aging. Mech Ageing Dev 2008; 129:460-466.
24. Königshoff M, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal? Am J Respir Cell Mol Biol 2010; 42:21-31.
25. Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for antireflux therapy? Eur Respir J 2012; 39:242-245.
26. Poh CH, Navarro-Rodrigues T, Fass R. Treatment of gastroesophageal reflux disease in the elderly. Am J Med 2010; 123:496-501.
27. Patti MG, Goldberg HI, Arcerito M, et al. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. Am J Surg 1996; 171:182-186. (Pubitemid 26028216)
28. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997; 111:1266-1272. (Pubitemid 27200083)
29. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1804-1808. (Pubitemid 29008818)
30. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27:136-142. (Pubitemid 43092677)
31. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded MDCT in patients with IPF. Eur Respir J 2012; 39:344-351.
32. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:1390-1394
33. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39:352-358
34. Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179:408-413.
35. Meyer KC, Raghu G. Patient evaluation. In Baughman RP, du Bois RM, editors. Interstitial lung disease: a practical approach. 2nd ed. New York: Springer; 2011. pp. 3-16.
36. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
37. Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181:832-837.
38. Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 2011; 38:761-769.
39. Kondoh Y, Taniguchi H, Kitaichi M, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. RespirMed 2006; 100:1753-1759. (Pubitemid 44283759)
40. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:431-440.
41. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58:143-148. (Pubitemid 36183002)
42. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140:221-229.
43. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1382-1389.
44. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172:488-493. (Pubitemid 41117395)
45. Edey AJ, Devaraj AA, Barker RP, et al. Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 2011; 21:1586-1593.
46. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746-752.
47. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:7-19.
48. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:459-466.
49. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174:803-809. (Pubitemid 44511662)
50. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
51. Meyer KC. Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:3-17
52. Frankel SK, Schwarz MI. Update in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2009; 15:463-469.
53. Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011; 17:348-354.
54. Egan JJ. Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient. Eur Respir Rev 2011; 20:114-117.
55. Kim R, Meyer KC. Therapies of interstitial lung disease-past, present, and future. Ther Adv Respir Dis 2008; 2:319-338.
56. NIH/NHLBI. NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis. http://www.news-medical .net/news/20111022/NIH-stops- tripledrug-therapy-clinical-trial-for-idiopathic-pulmonary-fibrosis.aspx. [Accessed on 12 January 2012]
57. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242. (Pubitemid 41697286)
58. Meyer KC, Decker C, Baughman R. Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. Clin Chest Med 2010; 31:565-588.
59. Kreider M, Hadjiliadis D, Kotloff RM. Candidate selection, timing of listing, and choice of procedure for lung transplantation. Clin Chest Med 2011; 32:199-211.
60. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745-755. (Pubitemid 43963375)
61. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011; 184:842-847.
62. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14:723-728.
63. Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39:125-132.
64. Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010; 104:1035-1041.
65. Holland AE, Hill CJ, Glaspole I, Goh N, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med 2012; 106:429-435.
66. Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care 2011; 56:783-789.
67. Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011; 38:987-990.
68. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136:772-778.
69. Rasche K, Orth M. Sleep and breathing in idiopathic pulmonary fibrosis. J Physiol Pharmacol 2009; 60 (Suppl 5):13-14.
70. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821-829.
71. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
72. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079-1087.
73. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-133. (Pubitemid 38056223)
74. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222-228.